Madrigal Pharmaceuticals MDGL announced an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. (Ribo) and its subsidiary, Ribocure Pharmaceuticals AB (Ribocure), covering six ...

Madrigal Pharmaceuticals (MASH) has reached an exclusive licensing agreement with China-based Suzhou Ribo Life Science to jointly develop treatments targeting a liver disease called metabolic ...

CONSHOHOCKEN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

Vida Health, a virtual, personalized obesity care provider that helps patients manage obesity, diabetes, and related conditions, today announced the expansion of its clinical portfolio to include ...

Creamy cassava mash with coconut, turmeric, chilies, and aromatic mustard seed topping US strikes another alleged drug-trafficking boat in Eastern Pacific Bitcoin rebounds as traders buy dip after 50% ...

This article originally appeared on HCPLive®. The FDA has granted breakthrough therapy designation (BTD) for pemvidutide for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). 1 ...

A soldier wounded in Korea in 1951 had better survival odds than soldiers wounded in World War II despite heavier casualties and harsher conditions. The difference was time. Mobile Army Surgical ...

Madrigal Pharmaceuticals (MDGL) announced on Friday an exclusive global license agreement with Pfizer (PFE) for ervogastat, an experimental therapy that could enhance the clinical effects of Rezdiffra ...

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its approved liver disease med Rezdiffra. Madrigal’s thyroid hormone ...

POCATELLO — Area residents can deliver holly-jolly haymakers while dashing and thrashing the night away when Mosh for Santa returns to the local Toys for Tots warehouse Saturday. The hardcore holidays ...